Contingency management and pre-exposure prophylaxis adherence support services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs
Sung M, Viera A, Esserman D, Tong G, Davidson D, Aiudi S, Bailey G, Buchanan A, Buchelli M, Jenkins M, John B, Kolakowski J, Lame A, Murphy S, Porter E, Simone L, Paris M, Rash C, Edelman E. Contingency management and pre-exposure prophylaxis adherence support services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs. Contemporary Clinical Trials 2022, 125: 107037. PMID: 36460267, PMCID: PMC9918697, DOI: 10.1016/j.cct.2022.107037.Peer-Reviewed Original ResearchConceptsAdherence support servicesHIV risk reductionPrEP adherenceContingency managementHybrid type 1 effectiveness-implementation trialHIV pre-exposure prophylaxisEffectiveness-implementation studyPre-exposure prophylaxisEffectiveness-implementation trialOpioid use disorderStrengths-based case managementRisk reductionSupport servicesCommunity-based programsPrEP initiationPrimary outcomeWeek 12Clinical trialsHIV preventionUse disordersCM sessionsCase managementBlood spotsPWIDStudy design